Etanercept

Immune system

Obstetrics

Preeclampsia

Infliximab

Tumor necrosis factor alpha

Adverse effect

Biology

Miscarriage

Adalimumab

Certolizumab pegol

Internal medicine

Immunology

Pregnancy

Genetics

Medicine

Expert Reviews in Molecular Medicine

Pregnancy is a complex biological process. The establishment and maintenance of foetal–maternal interface are pivotal events. Decidual immune cells and inflammatory cytokines play indispensable roles in the foetal–maternal interface. The disfunction of decidual immune cells leads to adverse pregnancy outcome. Tumour necrosis factor (TNF)- α , a common inflammatory cytokine, has critical roles in different stages of normal pregnancy process. However, the relationship between the disorder of TNF- α and adverse pregnancy outcomes, including preeclampsia (PE), intrauterine growth restriction (IUGR), spontaneous abortion (SA), preterm birth and so on, is still indefinite. In this review, we thoroughly reviewed the effect of TNF- α disorder on pathological conditions. Moreover, we summarized the reports about the adverse pregnancy outcomes (PE, IUGR, SA and preterm birth) of using anti-TNF- α drugs (infliximab, etanercept and adalimumab, certolizumab and golimumab) currently in the clinical studies. Overall, IUGR, SA and preterm birth are the most common adverse pregnancy outcomes of anti-TNF- α drugs. Our review may provide insight for the immunological treatment of pregnancy-related complication, and help practitioners make informed decisions based on the current evidences.

TNF-<i>α</i>/anti-TNF-<i>α</i>drugs and its effect on pregnancy outcomes

TNF-α/anti-TNF-αdrugs and its effect on pregnancy outcomes